IPO

Senores Pharmaceuticals Limited IPO

Mainboard

Listed On: Dec 30, 2024 at ₹ 600.0(NSE)

₹ 14858 /38 Shares

Check Allotment
Senores Pharmaceuticals IPO Details

20 Dec, 2024

Open Date

24 Dec, 2024

Close Date

26 Dec, 2024

Allotment Date

30 Dec, 2024

Listing Date

Issue Price

₹372-391 per equity share

Face Value

₹10 Per Equity Share

Listing at Group

BSE, NSE

Registrar

Link Intime India Private Ltd

List Price

600.0(NSE)

Listing Date

2024-12-30

Market Lot

Retail : 38 Shares (₹14,858/-)
S-HNI : 532 Shares (₹2,08,012/-)
B-HNI : 2,584 Shares (₹10,10,344/-)

Lead Manager

Equirus Capital Private LimitedAmbit Private Limited
Nuvama Wealth Management Limited

Issue Size

Total ₹582.11 Cr :
#Fresh Issue : 1,27,87,723 shares(aggregating up to ₹500.00 Cr) +
#OFS : 21,00,000 shares of ₹10(aggregating up to ₹82.11 Cr)

Retail Portion

10% (Number of Retail Applications: 38,981 Approx),
(Number of S-HNI Applications : 1,392 Approx),
(Number of B-HNI Applications : 2,784 Approx)

Subscription

93.41 times

IPO Docs

DRHP RHP ANCHOR

Senores Pharmaceuticals IPO Subscription Details

As onQIBNII
bNII   sNII		RetailTotal
Shares Offered / Reserved44,43,81722,21,909
15,18,605    7,03,304		14,81,27281,46,998
Day 1 - 20-12-24 05:00 PM0.01 x1.67
1.11 x   2.80 x		7.20 x1.78 x
Day 2 - 23-12-24 05:00 PM0.35 x24.48
20.14 x   33.15 x		38.32 x13.87 x
Day 3 - 24-12-24 05:00 PM94.66 x96.11
93.53 x   101.27 x		89.23 x93.41 x
Total No. of Applications: 37,01,011 (Approx)
Retail Subscription on the basis of Applications: Retail:77.82x BHNI:20.12x SHNI:106.99x times

Senores Pharmaceuticals Valuations

EPS Pre IPO

₹9.83/-

EPS Post IPO

₹13.86/-

P/E Pre IPO

39.77

P/E Post IPO

28.21

RoNW

23.60%

Senores Pharmaceuticals Company Financials All values are in ₹ Cr.

31-Mar-2431-Mar-2331-Mar-22
Assets621.88131.0559.15
Revenue217.3439.0214.63
Profit After Tax32.718.430.99

About The Company

Senores Pharmaceuticals is the world's leading research-driven pharmaceutical firm with a presence in several nations, engaged in the research and development, as well as manufacture of a myriad of pharmaceuticals products. The firm has thus built an independent niche in a regulated marketplace in US and Canada besides maintaining robust performance in emerging markets within 43 countries.

Senores Pharmaceuticals has strategically focused on specialty, underpenetrated, and complex pharmaceutical products and has emerged as the preferred partner for top-tier Indian and foreign pharmaceutical companies such as Prasco LLC, Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., Alkem Laboratories, Sun Pharmaceuticals, Dr. Reddy's Laboratories Inc., and Cipla USA Inc.

The company has capabilities in a variety of therapeutic areas and multiple dosage forms, from the manufacturing of critical care injectables and APIs. Senores Pharmaceuticals possesses a fast-growing portfolio with 182 products registered as of March 31, 2024, and a further 245 filings ongoing.

Senores Pharmaceuticals with 113 employees operating by working lean yet efficiently keeps the innovation, regulatory compliance as well as quality manufacturing along with high-value pharmaceutical solutions delivering. Its commitment to research development and partnerships makes it very key in advancing healthcare solution across global markets.

This IPO is going to be an exciting stage for the company, aiming at the strengthening of its position in the market, product development, and exploitation of growing opportunities within the global pharmaceutical sector.

Read More

Senores Pharmaceuticals - Strength and Weakness

Strength

Senores Pharmaceuticals has a US FDA-approved manufacturing facility in Atlanta, enhancing its ability to serve regulated markets.

he company’s Atlanta facility, approved by the DEA, can manufacture controlled substances, providing a competitive edge in the US market.

Senores Pharmaceuticals offers a one-stop CDMO solution, catering to pharmaceutical companies' development and manufacturing needs.

The company has built a strong product portfolio in emerging markets, focusing on complex products with less competition.

Weakness

The company’s reliance on third-party marketing partners and distributors exposes it to potential business disruptions if partnerships fail.

Strict adherence to quality standards is crucial for Senores Pharmaceuticals; any failure may lead to order cancellations and legal liabilities.

The company’s reliance on a few key customers makes it vulnerable to significant revenue loss if these customers terminate contracts.

Senores Pharmaceuticals - Promoter(s)

Pre Issue Share Holding: N/A%

Post Issue Share Holding: N/A%

Company Promoter(s)
  1. Swapnil Jatinbhai Shah
  2. Ashokkumar Vijaysinh Barot

Senores Pharmaceuticals IPO - Issue Objectives

  1. Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(Havix), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility
  2. Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company;
  3. Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary
  4. Funding the working capital requirements of the Company;
  5. Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (SPI)and Ratnatris Pharmaceutical Private Limited (Ratnatris), to fund their working capital requirements.
  6. Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.

Senores Pharmaceuticals IPO - Anchor Investors

Senores Pharmaceuticals IPO: Institutional investors invest Rs 261 crore via anchor book.

Domestic institutional investors like ICICI Prudential Mutual Fund, Aditya Birla Sun Life Insurance, Mahindra Manulife, Bank of India Mutual Fund, SBI General Insurance, Troo Capital, Meru Investment Fund and Edelweiss Life Insurance made investment in the company via anchor book.

Furthermore, Goldman Sachs, Societe Generale, Beacon Stone Capital, LC Pharos Multi Strategy Fund, Intergrated Global Strategies, and Fortune Hands Growth Fund also bought shares in the company via anchor book.

Other Details

Company Contact Details

Senores Pharmaceuticals

1101 to 1103, 11th floor,, South Tower, ONE 42 oppositeJayantilal Park, Ambali Bopal Road, Ahmedabad,-380054

Phone: +91-79-29999857

Email: cs@senorespharma.com

Website: https://senorespharma.com/

Registrar Contact Details

Link Intime India Private Ltd

Phone: +91-22-4918 6270

Email: senorespharma.ipo@linkintime.co.in

Website: https://linkintime.co.in/initial_offer/public-issues.html

Senores Pharmaceuticals IPO - FAQs

Ans. Senores Pharmaceuticals Limited IPO is a Mainboard IPO. The issue is priced at ₹372-391 per equity share. The minimum order quantity is 38 Shares. The IPO opens on Dec 20, 2024, and closes on Dec 24, 2024. Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Ans. The Senores Pharmaceuticals Limited IPO opens on Dec 20, 2024 and closes on Dec 24, 2024.

Ans. The size of Senores Pharmaceuticals Limited IPO is Total ₹582.11 Cr : #Fresh Issue : 1,27,87,723 shares(aggregating up to ₹500.00 Cr) + #OFS : 21,00,000 shares of ₹10(aggregating up to ₹82.11 Cr).

Ans. The IPO price band is set between ₹372-391 per equity share.

Ans. To apply for Senores Pharmaceuticals Limited IPO IPO, follow the steps given below:

  • - Open the IPO Ji App or Website
  • - Find Senores Pharmaceuticals Limited IPO in the List of IPOs
  • - Press "Apply" Button
  • - Select Your Demat Account
  • - Select Your Shares Quantity and Submit
  • - Track Your IPO Status

Ans. The share allotment date of Senores Pharmaceuticals Limited IPO is Dec 26, 2024.

Ans. The Senores Pharmaceuticals Limited IPO will be listed on Dec 30, 2024.

Ans. Follow the steps to check the allotment status for Senores Pharmaceuticals Limited IPO here.